Charles Schwab Investment Management Inc Actinium Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 72,093 shares of ATNM stock, worth $92,999. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,093
Previous 83,577
13.74%
Holding current value
$92,999
Previous $618,000
78.16%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ATNM
# of Institutions
74Shares Held
8.31MCall Options Held
65.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$2.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$885,1370.0% of portfolio
-
State Street Corp Boston, MA603KShares$777,4170.0% of portfolio
-
Acadian Asset Management LLC Boston, MA454KShares$585,2650.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.5M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...